Johnson & Johnson’s prostate cancer drug shrinks tumours in early-stage trial

JNJ-6143 demonstrates strong PSA reduction in advanced cases

Johnson & Johnson’s prostate cancer drug shrinks tumours in early-stage trial
JNJ-6143 demonstrates strong PSA reduction in advanced cases